Showing results (31-40 of 109) with videos related to

Sort By:
Pageof 11
Cancers|June 13, 2025
Efficacy and Safety of TROP-2-Targeting Antibody-Drug Conjugate Treatment in Previously Treated Patients with Advanced Non-Small Cell Lung Cancer: A Systematic Review and Pooled Analysis of Reconstructed Patient DataSara Stumpo, Andrea Carlini, Francesco Mantuano, et al.
JCO Precision Oncology|June 1, 2023
First-Generation Epidermal Growth Factor Receptor Inhibitors Plus Antiangiogenic Drugs Versus Third-Generation Epidermal Growth Factor Receptor Inhibitors in Advanced Non-Small-Cell Lung Cancer: A Meta-AnalysisMirta Mosca, Nicole Conci, Alessandro Di Federico, et al.
Anti-Cancer Drugs|March 4, 2021
Single-agent carboplatin in extensive disease small-cell lung cancer patient with liver failure: a case report within the experience of a single institutionAlessandro Di Federico, Elisa Andrini, Monia Sisi, et al.
Translational Oncology|August 17, 2022
Targeting tumor microenvironment for cholangiocarcinoma: Opportunities for precision medicineRiccardo Carloni, Alessandro Rizzo, Angela Dalia Ricci, et al.
Expert Opinion on Emerging Drugs|April 4, 2024
Non-small cell lung cancer: an update on emerging EGFR-targeted therapiesValentina Favorito, Ilaria Ricciotti, Andrea De Giglio, et al.
Cancers|July 27, 2022
Genomic Landscape, Clinical Features and Outcomes of Non-Small Cell Lung Cancer Patients Harboring <i>BRAF</i> Alterations of Distinct Functional ClassesAlessandro Di Federico, Andrea De Giglio, Francesco Gelsomino, et al.
Current Oncology (Toronto, Ont.)|July 25, 2022
Intensive Follow-Up Program and Oncological Outcomes of Biliary Tract Cancer Patients after Curative-Intent Surgery: A Twenty-Year Experience in a Single Tertiary Medical CenterAlessandro Rizzo, Riccardo Carloni, Giorgio Frega, et al.
Cancer Control : Journal of the Moffitt Cancer Center|December 28, 2020
Targeting BRAF-Mutant Biliary Tract Cancer: Recent Advances and Future ChallengesAlessandro Rizzo, Alessandro Di Federico, Angela Dalia Ricci, et al.
Future Medicinal Chemistry|August 23, 2022
Advances in novel systemic therapies for advanced hepatocellular carcinomaRiccardo Carloni, Alessandro Rizzo, Antonio Cusmai, et al.
Future Oncology (London, England)|February 3, 2022
Dual immune checkpoint blockade in hepatocellular carcinoma: where do we stand?Riccardo Carloni, Alessandro Rizzo, Angela Dalia Ricci, et al.
Pageof 11